Roche and Zealand Pharma reported Phase 2 data for petrelintide showing roughly 10.7% mean placebo‑controlled weight loss at 42 weeks, falling short of investor expectations and triggering a sharp drop in Zealand’s share price. Analysts noted the result compares unfavorably with higher weight‑loss signals from rival programs and suggested limited differentiation in a crowded obesity market. Zealand characterized the data as supportive of tolerability and a viable path to Phase 3, highlighting a favorable safety profile and the potential to optimize dosing. The company plans to advance a Phase 3 program later this year despite investor skepticism about commercial competitiveness. Market reaction reflects the hypercompetitive GLP‑1 and amylin‑adjacent landscape, where modest efficacy gaps can materially affect uptake and pricing power.